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Use of the plasma CTX for assessing the 
bone activity of the mandible among 
osteopenic and osteoporotic patients
Abstract: The aim of this study was to determine whether the plasma 
CTX bone remodeling marker is useful for indicating the bone meta-
bolic activity level of the mandible. Thirty-six patients were selected; 
all were postmenopausal and aged 50 years or over. In accordance with 
the WHO criteria for osteoporosis, a control group was set up (n = 10) 
in which the T-score was greater than –1 and a diseased group with T-
score less than –1. Using MDP-99mTc samples, the radioisotope uptake in 
the femoral neck (R2) and mandibular body (R1) was analyzed. A third 
examination was performed using the plasma CTX biochemical bone-
modeling marker. The inferential results for the diseased group showed 
that Ln(R1) presented a statistically significant linear relationship with 
Ln(CTx) (p = 0.067) and with the T-score (p = 0.018). The plasma CTX 
bone remodeling marker is useful for monitoring the bone metabolic ac-
tivity of the mandible.
Descriptors: Biological markers; Bone diseases, metabolic; Mandible.
Introduction
Osteoporosis is a disease of the skeleton characterized by decreased 
bone mineral density (BMD). This compromises the bone tissue micro-
architecture and predisposes the individual to increased risk of fracture.1 
The World Health Organization (WHO) has defined osteoporosis in 
white women as any bone mineral density measurement that is 2.5 stan-
dard deviations or more (T-score < –2.5) below the expected value for 
healthy young individuals (20-45 years of age).2 Patients with diminished 
bone mass frequently undergo anti-reabsorptive therapy using bisphos-
phonates, which have a significant modifying effect on bone turnover, 
and such patients may present a suppressed capacity for remodeling.3
The mandibular bone mass is subject to the same influences as the re-
mainder of the skeleton and is affected by the action of the drugs used in 
treating osteoporosis.4 Thus, for dentists to be able to decide whether it 
is opportune to intervene surgically in relation to bone tissue, the degree 
of bone modeling occurring in maxillary bones needs to be known5. The 
greatest fear is osteonecrosis of the jaws,6,7 particulary for those patients 
that have used bisphosphonates intravenously for treating metastatic can-
cer disease of bones such as breast cancer, multiple myeloma and pros-
tatic cancer. It is in this respect that the use of biochemical markers for 
bone remodeling may contribute towards this analysis.
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The biochemical bone reabsorption marker 
known as plasma CTX8 allows dynamic assessment 
of the level of bone tissue remodeling based on anal-
ysis of carboxyterminal telopeptide fragments of 
type I collagen that result from osteoclastic9 action 
occurring within the bone matrix on its crosslink-
forming interlinking molecules, pyrrolidine (PYD) 
and deoxypyrrolidine (DPD). This marker presents 
better histomorphological10 correlations with the re-
modeling changes that occur in the bone tissue. It is 
a test that is easy to perform, with minimal discom-
fort for patients and without exposure to ionizing ra-
diation, and it can be repeated whenever requested, 
without requiring a large time interval since the pre-
vious examination. This is in contrast with the bone 
densitometry examination, for which a minimum 
time interval of six months to one year is required in 
order to detect a possible change in bone mass.
A bone scintigraphy examination was performed 
with the aim of determining the level of radioisotope 
uptake in the regions of the femoral neck and the 
mandibular body, in order to observe any possible 
functional abnormalities related to remodeling.11,12
The aim of the present study was to determine 
the effectiveness of using plasma CTX, a biochemi-
cal marker for bone remodeling, in assessing the 
bone metabolic activity level of the mandible.
Method
Subjects
For this study, 36 postmenopausal female pa-
tients aged 50 years or over were selected and di-
vided into two groups. The first group consisted of 
26 patients who presented diminished bone mineral 
density (among whom 14 were using alendronate): 
16 were considered to be osteopenic, with T-scores 
of less than –1 and greater than or equal to –2.5, and 
10 were considered to be osteoporotic, with T-scores 
of less than –2.5, thus following the WHO criteria 
for osteoporosis.1 The second group was formed by 
10 individuals who were considered to be normal. 
All these individuals were selected retrospectively 
from the database of the osteoporosis outpatient 
clinic of the Department of Endocrinology of the 
Federal University of São Paulo (UNIFESP).
Patients presenting diseases that might have af-
fected their bone mass, such as chronic renal insuf-
ficiency, hyperparathyroidism, hyperthyroidism or 
liver disease, were excluded from this investigation. 
Likewise, patients were excluded if they presented 
any type of neoplasia, because of the possibility 
that bone metastasis could have occurred.7 The use 
of corticoids and anti-convulsive13 medications was 
also an exclusion criterion.
Following an oral cavity examination, only the 
patients with no teeth at all or with no teeth in the 
region of the mandibular body were selected. This 
was done in order to avoid local causes that might 
interfere with the bone reabsorption in these regions. 
This study gained prior approval from the Research 
Ethics Committee of the Federal University of São 
Paulo, and all the subjects voluntarily agreed to par-
ticipate in the study.
Bone densitometry examination
Bone densitometry examination using DXA 
(Dual Energy X-ray Absorptiometry) was used as 
the criterion for selecting the patients with abnor-
mal and normal bone mass.
All the patients were positioned in horizontal 
dorsal decubitus for the bone mineral density (BMD) 
measurement. The examinations were all performed 
using the DPX-L apparatus (Lunar, Madison, Cali-
fornia, USA), coefficient of variation (CV) with alu-
miniun phantom is 1%, and the DPX-IQ software, 
version 4.7 (Lunar, Madison, California, USA). 
Readings were made in the region of the neck of the 
right femur. We chose to compare the femoral neck 
with the region of the mandibular body because the 
anatomical structure of the femoral neck is more 
corticalized and in this respect resembles the man-
dible, whereas the vertebral structures are predomi-
nantly trabecular.14,15
Bone scintigraphy examination
In order to observe any possible functional ab-
normalities related to remodeling12 a bone scintig-
raphy examination was performed. Hence, around 
1 ml of radiolabeled agent containing MDP-99mTc 
equivalent to 30 mCi was administered endove-
nously.11 The images were acquired by means of the 
LFOV single-head APEX SPX4 apparatus (Elscint, 
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Haifa, Israel). With the aim of avoiding reading er-
rors due to background radiation coming from soft 
tissue, an index was established based on the ratio 
between the scintillation count observed in the bone 
tissue and the count in the soft tissue adjacent to the 
Region of Interesting (ROI) under examination. For 
the region of the femur, this area corresponded to 
the lateral part of the thigh and, for the region of 
the mandible, this area selected was the retromolar 
region beside the soft tissue of the adjacent lateral 
cervical area. Thus, two indices named R1 and R2 
were obtained, referring respectively to the mandi-
ble and the femur.
Plasma CTX bone marker examination
Biochemical markers for bone remodeling can be 
defined as substances that depict bone formation or 
reabsorption.9 It also better reflects the calcium ki-
netics and is sensitive to small changes in the bones 
like those that occur over the course of osteoporo-
sis.16 Because bone remodeling markers are subject 
to circadian17 influence, the time of day for data col-
lection was standardized such that the patients were 
always asked to come at the start of the morning, 
after having fasted for eight hours.
Statistical analysis
Twenty-six patients with diminished bone mass 
were selected, among whom 14 were using alendro-
nate. The group of patients who were considered to 
be osteopenic or osteoporotic were analyzed togeth-
er because what was important was the fact that 
they presented bone mass abnormalities, regard-
less of the extent, for comparison with the normal 
group. The relationships between R1, T-score and 
CTX were analyzed by means of multiple logistic 
regression, and regression models were adjusted for 
each of the groups considered. The relationship be-
tween R1 and CTX was analyzed by means of simple 
linear regression. With the aim of bringing the val-
ues closer together and diminishing the variability 
among the data gathered in this study, the resource 
of Naperian logarithms (which is frequently used 
in statistical analysis) was applied, with the aim of 
obtaining a relationship that was more linear, since 
such relationships are easier to analyze.
The SPSS for windows 11.5 (SPSS Inc., Chicago, 
Illinois, USA) was used for carrying out the sta-
tistical analysis. In all cases, the level for rejecting 
the nullity hypothesis was always set at the level of 
p ≤ 0.10 (10%), and statistically significant values 
were marked with an asterisk (*). 
Results
Dispersion and boxplot graphs were constructed, 
which depict the distribution of the magnitudes in 
the two study groups (Graphs 1 and 2). It is impor-
tant to emphasize that the T-score only provides the 
bone mineral density value obtained at the time of 
the examination, which does not necessarily reflect 
the true metabolic condition of the bone tissue, as 
can be seen in the dispersion graph (Graph 1).
Given the nature of the variables studied, sum-
mary measurements were calculated (Tables 1, 2 
and 3).
The inferential results for the diseased group of 
patients showed that Ln(R1), i.e. the Naperian loga-
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Graph 1 - CTX and T-score dispersion graph for the two 
groups.
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rithm of R1, presented a statistically significant lin-
ear relationship with Ln(CTx) (Naperian logarithm 
of CTx) (p = 0.067) and with the T-score (p = 0.018), 
as can be seen in the summary of the inferential re-
sults (Table 4).
The boxplot graphical analysis considering the 
CTX values for the two groups of patients (Graph 2) 
showed that there was a more homogenous distri-
bution for the control group. On the other hand, 
for the group of patients with BMD abnormalities 
(diseased group), the distribution was less homog-
enous and this observation was compatible with the 
varying amounts of CTX that were released into the 
bloodstream and detected by this type of test.
Thus, it could be seen from the dispersion graph 
(Graph 1) that the relationship between the metabol-
ic activity of the mandible (R1) and the CTX values 
among the diseased individuals (both expressed in 
the form of Naperian logarithms) presented statisti-
cal significance, with a descriptive level of p = 0.067 
for this sample of 26 diseased patients.
Thus, for the diseased group, the value of Ln(R1) 
can be calculated from the T-score and Ln(CTx), by 
means of the regression equation:
Table 1 - Measurements for age, mandible, soft tissue and R1, for the two study groups.
Measur.
Age Mandible Soft tissue R1
Control Diseased Control Diseased Control Diseased Control Diseased
N 10 26 10 26 10 26 10 26
Mean 58.80 67.54 11549.50 13281.50 6901.60 7452.35 1.69 1.84
SD  4.85  9.51  1810.24  2138.34 1439.07 1404.32 0.13 0.45
Minimum 51.00 51.00  8390.00  8328.00 4801.00 4883.00 1.46 1.21
Maximum 68.00 85.00 14253.00 18053.00 9785.00 9785.00 1.86 2.89
N = sample size; SD = standard deviation; Measur = measurements.
Measur.
Femur Thigh R2
Control Diseased Control Diseased Control Diseased
N 10 26 10 26 10 26
Mean 9192.80 10028.31 2798.90 3616.88 3.36 2.94
SD  2607.46  2106.24  542.70  764.63 0.91 1.09
Minimum  6440.00  6644.00 1567.00 2473.00 2.10 1.51
Maximum 12799.00 14802.00 3269.00 4804.00 4.47 5.72
N = sample size; SD = standard deviation; Measur = measurements.
Table 2 - 
Measurements for the 
femur, thigh and R2, in 
the two study groups.
Measur.
BMD/neck T-score/neck CTX (ng/ml)
Control Diseased Control Diseased Control Diseased
N 10 26 10 26 10 26
Mean 0.99 0.73  0.09 −2.18 0.20 0.27
SD 0.10 0.08  0.80  0.65 0.08 0.25
Minimum 0.86 0.58 −0.97 −3.33 0.05 0.01
Maximum 1.18 0.92  1.30 −1.15 0.30 0.81
N = sample size; SD = standard deviation; Measur = measurements.
Table 3 - 
Measurements for 
BMD/neck, T-score/
neck, and CTX, in the 
two study groups.
Ln(R1) = 0.300 − 0.200 × Tscore + 0.082 × Ln(CTx)
The following is the interpretation from the pa-
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rameters calculated in the above equation: The de-
crease in Ln(R1) for each one-unit increase in the 
T-score is –0.200; The increase in Ln(R1) for each 
one-unit increase in Ln(CTx) is 0.082. The results 
from adjusting the regression model for the control 
group showed that T-score2 (square of the T-score) 
(p = 0.038) and Ln(CTx) (p = 0.172) were linearly 
associated with Ln(R1).
Discussion
The mandible body area was elected in order to 
avoid anatomical overlapping structures and also 
being a region of greater remodelative stimulus, due 
to the insertion of muscles, and therefore subject to 
greater metabolic influence.12,18 The reason why an 
edentulous area was chosen was to avoid the pos-
sibility of irritative local factors such as periodontal 
disease, poorly adapted prostheses or dental ano-
malies (thus not a result from a metabolic systemic 
source) that could in any way represent a local fac-
tor of absorption and interfere in the rate of radio-
isotope uptake. Nevertheless, it is supposed that the 
same metabolic systemic influences also may occur 
in the upper jaw and in toothed patients.
In analyzing the radioisotope uptake rates (Ta-
bles 1 and 2), it was observed that R1 was around 
1.5 times smaller than R2. This is due to the fact that 
the femoral neck is subject to the action of greater 
loads than experienced by the mandible, and also 
because it presents greater bone volume. It was also 
observed that the R1 index was more heterogenous in 
the diseased group than in the control group, which 
can be explained by the fact that many of these dis-
eased patients (14 individuals) presented low bone 
turnover because they were using anti-reabsorptive 
medication, thereby giving rise to this effect in the 
analysis for this group. The same can be seen in the 
analysis on the R2 index, although this presented a 
higher median value because of the abovementioned 
reasons. In this group, for T-score values close to 
the limit of normality, high CTX values (normal 
reference values for male: 0.300 ng/ml 30-50 years; 
0.304 ng/ml 50-70 years; 0.394 ng/ml > 70 years 
and female: 0.299 ng/ml premenopausal; 0.556 ng/
ml postmenopausal)19,20 can be seen, thus indicating 
a high degree of bone reabsorption. On the other 
hand, T-score values that are considered low, as a 
result of possible elevation of resorptive activity that 
characterizes low BMD, present low CTX values 
that come close to zero as a consequence of the low 
level of bone remodeling. This can be explained by 
the use of anti-reabsorptive agents.
The CTX values for the diseased group (Graph 1) 
were shown to be coherent with the clinical findings 
and ranged from values close to zero (explained by 
the use of anti-reabsorptive medication) to high val-
ues of CTX among the patients who were not using 
alendronate but presented a high degree of bone re-
modeling.
 All this evidence is concordant with the litera-
ture,21 in which CTX is indicated as an efficient and 
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Graph 2 - Boxplot of CTX for the control and diseased 
groups.
Table 4 - Inferential results from the multiple linear regres-
sion model for the diseased group compared to Ln(R1).
Model Coefficients Standard error Descriptive level (p)
Constant 0.300 0.147 0.053*
T-score  −0.200 0.078 0.018*
Ln( Tx) 0.082 0.042 0.067*
Ln = Naperian logarithm of CTX.*Statistically significant values are marked 
with an asterisk.
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reliable clinical method for monitoring not only the 
metabolic activity of bone tissue but also the thera-
peutic efficacy of the drugs used in treating osteo-
porosis.13,22 It is important to emphasize that cor-
relations must be made while always taking into 
account each patient’s clinical information since, 
otherwise, errors may be made in interpreting the 
data. In the light of patient populations that are sub-
ject to factors that compromise their bone metabo-
lism, it becomes necessary to assess the level of the 
metabolic activity of their bone tissue, independent 
of the BMD values that they may present.
Conclusion
This result makes it possible for us to state that 
the plasma CTX test is useful for estimating the 
bone metabolic activity of the mandible. Further 
studies are necessary to understand the role played 
by the use of anti-reabsorptive medication on the 
jaws.
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